InspireMD to Announce Six-Month Results from the MGuard™ Embolic Protection Stent (EPS) MASTER Trial at EuroPCR

Embolic protection stent developer, InspireMD, Inc. has announced a robust schedule of educational events and data presentations at next week’s EuroPCR (May 21-24 Paris), culminating in the first presentation of 6-month results from the MASTER (MGuardfor Acute STElevation Reperfusion) trial of the Company’s MGuard™ Embolic Protection Stent

InspireMD to Announce Six-Month Results from the MGuard™ Embolic Protection Stent (EPS) MASTER Trial at EuroPCR (via PR Newswire)

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ —  -Strong Conference Presence to Include Presentations/EducationalEvents Featuring the MGuard™ Embolic Protection Stent-  – Company to Host Conference Call on Thursday, May 23rd to Review MASTER Data – InspireMD, Inc. (“InspireMD” or the…

published: May 17, 2013 in: Cardio, Clinical Studies/Trials

Most read

Latest

^